uniprot_id	Orig_AA	Position_AA	Mut_AA	X6	gene	protein_entry	protein_entry_pos	Name	AlnPosition	FastaPosition	FastaAA	uniprot_mut	Uniprot_mutation	act_list
Q9UM73	F	1174	L	/note=""F -> L (in NBLST3; somatic mutation; constitutively activated; retained in the endoplasmic reticulum and Golgi compartments; dbSNP:rs863225281)"" /evidence=""ECO:0000269|PubMed:18923523, ECO:0000269|PubMed:18923525, ECO:0000269|PubMed:21242967"" /id=""VAR_063857""	ALK	ALK_Q9UM73	ALK_Q9UM73_1174	ALK_Q9UM73	6583	1174	F	F1174L	Q9UM73_F1174L	A
Q9UM73	F	1174	V	/note=""F -> V (in NBLST3; somatic mutation; constitutively activated; retained in the endoplasmic reticulum and Golgi compartments; dbSNP:rs281864719)"" /evidence=""ECO:0000269|PubMed:18923523, ECO:0000269|PubMed:21242967"" /id=""VAR_063858""	ALK	ALK_Q9UM73	ALK_Q9UM73_1174	ALK_Q9UM73	6583	1174	F	F1174V	Q9UM73_F1174V	A
Q9UM73	R	1275	Q	/note=""R -> Q (in NBLST3; constitutively activated; retained in the endoplasmic reticulum and Golgi compartments; dbSNP:rs113994087)"" /evidence=""ECO:0000269|PubMed:18724359, ECO:0000269|PubMed:18923523, ECO:0000269|PubMed:18923525, ECO:0000269|PubMed:21242967"" /id=""VAR_063865""	ALK	ALK_Q9UM73	ALK_Q9UM73_1275	ALK_Q9UM73	6859	1275	R	R1275Q	Q9UM73_R1275Q	A
O14965	I	57	V	/note=""I -> V (increased kinase activity; dbSNP:rs1047972)"" /evidence=""ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:15867347, ECO:0000269|PubMed:16011022, ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9153231, ECO:0000269|PubMed:9514916, ECO:0000269|PubMed:9771714"" /id=""VAR_030842""	AURKA	AURKA_O14965	AURKA_O14965_57	AURKA_O14965	6392	57	I	I57V	O14965_I57V	A
P15056	R	671	K	/note=""R->K: Increased kinase activity and stability in response to EGF treatment."" /evidence=""ECO:0000269|PubMed:21917714""	BRAF	BRAF_P15056	BRAF_P15056_671	BRAF_P15056	7001	671	R	R671K	P15056_R671K	A
Q8IWQ3	T	174	E	/note=""T->E: Constitutively activated."" /evidence=""ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:18339622, ECO:0000269|PubMed:22798068""	BRSK2	BRSK2_Q8IWQ3	BRSK2_Q8IWQ3_174	BRSK2_Q8IWQ3	6908	174	T	T174E	Q8IWQ3_T174E	A
Q8IWQ3	T	443	A	/note=""T->A: Constitutively activated. Promotes formation of actin stress fibers."" /evidence=""ECO:0000269|PubMed:22669945""	BRSK2	BRSK2_Q8IWQ3	BRSK2_Q8IWQ3_443	BRSK2_Q8IWQ3	7298	443	T	T443A	Q8IWQ3_T443A	A
Q00536	S	153	A	/note=""S->A: Constitutively activated, due to loss of an inhibitory phosphorylation site. Increases interaction with CCNY."" /evidence=""ECO:0000269|PubMed:22184064, ECO:0000269|PubMed:22798068""	CDK16	CDK16_Q00536	CDK16_Q00536_153	CDK16_Q00536	6456	153	S	S153A	Q00536_S153A	A
Q9BWU1	Y	32	H	/note=""Y -> H (in DEE87; fails to rescue neurologic phenotypes in a Drosophila model system; increased protein kinase activity; dbSNP:rs1236246272)"" /evidence=""ECO:0000269|PubMed:32330417, ECO:0000269|PubMed:33134521, ECO:0000269|PubMed:33495529"" /id=""VAR_084395""	CDK19	CDK19_Q9BWU1	CDK19_Q9BWU1_32	CDK19_Q9BWU1	6479	32	Y	Y32H	Q9BWU1_Y32H	A
Q16832	L	610	P	/note=""L -> P (in WRCN; increased autophosphorylation in patient fibroblasts)"" /evidence=""ECO:0000269|PubMed:30449416"" /id=""VAR_081931""	DDR2	DDR2_Q16832	DDR2_Q16832_610	DDR2_Q16832	6553	610	L	L610P	Q16832_L610P	A
Q16832	Y	740	C	/note=""Y -> C (in WRCN; increased autophosphorylation in patient fibroblasts)"" /evidence=""ECO:0000269|PubMed:30449416"" /id=""VAR_081932""	DDR2	DDR2_Q16832	DDR2_Q16832_740	DDR2_Q16832	6869	740	Y	Y740C	Q16832_Y740C	A
P00533	E	709	G	/note=""E -> G (found in a lung cancer sample; constitutively activated kinase with higher levels of basal autophosphorylation; more sensitive to gefitinib than wild- type; dbSNP:rs397517085)"" /evidence=""ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628"" /id=""VAR_069498""	EGFR	EGFR_P00533	EGFR_P00533_709	EGFR_P00533	6465	709	E	E709G	P00533_E709G	A
P00533	G	719	S	/note=""G -> S (found in a lung cancer sample; somatic mutation; strongly increased kinase activity; constitutively activated kinase with higher levels of basal autophosphorylation; more sensitive to gefitinib than wild- type; dbSNP:rs28929495)"" /evidence=""ECO:0000269|PubMed:15118125, ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:17349580"" /id=""VAR_019297""	EGFR	EGFR_P00533	EGFR_P00533_719	EGFR_P00533	6475	719	G	G719S	P00533_G719S	A
P00533	S	768	I	/note=""S -> I (found in a lung cancer sample; constitutively activated kinase with higher levels of basal autophosphorylation; more sensitive to gefitinib than wild- type; dbSNP:rs121913465)"" /evidence=""ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628"" /id=""VAR_069502""	EGFR	EGFR_P00533	EGFR_P00533_768	EGFR_P00533	6582	768	S	S768I	P00533_S768I	A
P00533	T	790	M	/note=""T -> M (found in a lung cancer sample; increased kinase activity; dbSNP:rs121434569)"" /evidence=""ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:18227510"" /id=""VAR_026098""	EGFR	EGFR_P00533	EGFR_P00533_790	EGFR_P00533	6639	790	T	T790M	P00533_T790M	A
P00533	L	858	R	/note=""L -> R (found in a lung cancer sample; somatic mutation; constitutively activated enzyme with strongly increased kinase activity; more sensitive to gefitinib than wild-type; dbSNP:rs121434568)"" /evidence=""ECO:0000269|PubMed:15118125, ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:17349580"" /id=""VAR_019298""	EGFR	EGFR_P00533	EGFR_P00533_858	EGFR_P00533	6854	858	L	L858R	P00533_L858R	A
P00533	L	861	Q	/note=""L -> Q (found in a lung cancer sample; constitutively activated kinase with higher levels of basal autophosphorylation; more sensitive to gefitinib than wild- type; dbSNP:rs121913444)"" /evidence=""ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793"" /id=""VAR_026102""	EGFR	EGFR_P00533	EGFR_P00533_861	EGFR_P00533	6863	861	L	L861Q	P00533_L861Q	A
P00533	V	689	M	/note=""V->M: Constitutively activated kinase."" /evidence=""ECO:0000269|PubMed:19560417""	EGFR	EGFR_P00533	EGFR_P00533_689	EGFR_P00533	6445	689	V	V689M	P00533_V689M	A
P00533	T	693	A	/note=""T->A: Increased phosphorylation."" /evidence=""ECO:0000269|PubMed:19560417""	EGFR	EGFR_P00533	EGFR_P00533_693	EGFR_P00533	6449	693	T	T693A	P00533_T693A	A
P00533	E	1005	R	/note=""ED->RK: Constitutively activated kinase."" /evidence=""ECO:0000269|PubMed:19563760""	EGFR	EGFR_P00533	EGFR_P00533_1005	EGFR_P00533	7165	1005	E	E1005R	P00533_E1005R	A
P00533	D	1006	K	/note=""ED->RK: Constitutively activated kinase."" /evidence=""ECO:0000269|PubMed:19563760""	EGFR	EGFR_P00533	EGFR_P00533_1006	EGFR_P00533	7166	1006	D	D1006K	P00533_D1006K	A
Q15303	Q	646	C	/note=""Q->C: Constitutively activated kinase."" /evidence=""ECO:0000269|PubMed:17120616""	ERBB4	ERBB4_Q15303	ERBB4_Q15303_646	ERBB4_Q15303	6394	646	Q	Q646C	Q15303_Q646C	A
P07332	L	145	P	/note=""L->P: Constitutively activated kinase that can act as oncogene. Promotes myeloid cell survival and proliferation."" /evidence=""ECO:0000269|PubMed:11509660, ECO:0000269|PubMed:15485904""	FES	FES_P07332	FES_P07332_145	FES_P07332	6049	145	L	L145P	P07332_L145P	A
P11362	N	546	K	/note=""N -> K (in ECCL; somatic mutation; activating mutation; strongly increased speed of the first autophosphorylation and loss of the normal sequential order of autophosphorylation; dbSNP:rs779707422)"" /evidence=""ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:26942290"" /id=""VAR_075853""	FGFR1	FGFR1_P11362	FGFR1_P11362_546	FGFR1_P11362	6596	546	N	N546K	P11362_N546K	A
P22607	G	380	R	/note=""G -> R (in keratinocytic non-epidermolytic nevus and ACH; very common mutation; constitutively activated kinase with impaired internalization and degradation, resulting in prolonged FGFR3 signaling; dbSNP:rs28931614)"" /evidence=""ECO:0000269|PubMed:10611230, ECO:0000269|PubMed:12297284, ECO:0000269|PubMed:16841094, ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:7847369, ECO:0000269|PubMed:8078586, ECO:0000269|PubMed:8599935"" /id=""VAR_004155""	FGFR3	FGFR3_P22607	FGFR3_P22607_380	FGFR3_P22607	6373	380	G	G380R	P22607_G380R	A
P22607	K	650	E	/note=""K -> E (in KERSEB, TD2, TGCT and BLC; bladder transitional cell carcinoma; somatic mutation; constitutively activated kinase with impaired internalization and degradation, resulting in prolonged FGFR3 signaling; dbSNP:rs78311289)"" /evidence=""ECO:0000269|PubMed:10471491, ECO:0000269|PubMed:11294897, ECO:0000269|PubMed:12297284, ECO:0000269|PubMed:14534538, ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:17145761, ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:19855393, ECO:0000269|PubMed:7773297, ECO:0000269|PubMed:8754806, ECO:0000269|PubMed:9207791"" /id=""VAR_004160""	FGFR3	FGFR3_P22607	FGFR3_P22607_650	FGFR3_P22607	6905	650	K	K650E	P22607_K650E	A
P22607	K	650	M	/note=""K -> M (in KERSEB, ACH, TD1 and SADDAN; constitutively activated kinase with impaired internalization and degradation, resulting in prolonged FGFR3 signaling; dbSNP:rs121913105)"" /evidence=""ECO:0000269|PubMed:10053006, ECO:0000269|PubMed:10671061, ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:9207791"" /id=""VAR_004161""	FGFR3	FGFR3_P22607	FGFR3_P22607_650	FGFR3_P22607	6905	650	K	K650M	P22607_K650M	A
P22607	K	650	Q	/note=""K -> Q (in hypochondroplasia and BLC; in hypochondroplasia the form is milder than that seen in individuals with the K-540 or M-650 mutations; constitutively activated kinase; dbSNP:rs78311289)"" /evidence=""ECO:0000269|PubMed:11055896, ECO:0000269|PubMed:11314002, ECO:0000269|PubMed:8754806"" /id=""VAR_018390""	FGFR3	FGFR3_P22607	FGFR3_P22607_650	FGFR3_P22607	6905	650	K	K650Q	P22607_K650Q	A
P22607	K	650	D	/note=""K->D: Constitutively activated kinase.""	FGFR3	FGFR3_P22607	FGFR3_P22607_650	FGFR3_P22607	6905	650	K	K650D	P22607_K650D	A
P22607	K	650	L	/note=""K->L: Constitutively activated kinase.""	FGFR3	FGFR3_P22607	FGFR3_P22607_650	FGFR3_P22607	6905	650	K	K650L	P22607_K650L	A
P09769	Y	523	F	/note=""Y->F: Strongly increased catalytic activity. Functions as oncogene."" /evidence=""ECO:0000269|PubMed:1737799""	FGR	FGR_P09769	FGR_P09769_523	FGR_P09769	7139	523	Y	Y523F	P09769_Y523F	A
P36888	D	835	E	/note=""D -> E (in acute lymphoblastic leukemia patients and acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121913487)"" /evidence=""ECO:0000269|PubMed:11290608, ECO:0000269|PubMed:14504097"" /id=""VAR_065679""	FLT3	FLT3_P36888	FLT3_P36888_835	FLT3_P36888	6863	835	D	D835E	P36888_D835E	A
P36888	D	835	H	/note=""D -> H (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121913488)"" /evidence=""ECO:0000269|PubMed:11290608, ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097"" /id=""VAR_065680""	FLT3	FLT3_P36888	FLT3_P36888_835	FLT3_P36888	6863	835	D	D835H	P36888_D835H	A
P36888	D	835	N	/note=""D -> N (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121913488)"" /evidence=""ECO:0000269|PubMed:11290608"" /id=""VAR_065681""	FLT3	FLT3_P36888	FLT3_P36888_835	FLT3_P36888	6863	835	D	D835N	P36888_D835N	A
P36888	D	835	V	/note=""D -> V (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121909646)"" /evidence=""ECO:0000269|PubMed:11290608"" /id=""VAR_065682""	FLT3	FLT3_P36888	FLT3_P36888_835	FLT3_P36888	6863	835	D	D835V	P36888_D835V	A
P36888	D	835	Y	/note=""D -> Y (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121913488)"" /evidence=""ECO:0000269|PubMed:11290608, ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097"" /id=""VAR_065683""	FLT3	FLT3_P36888	FLT3_P36888_835	FLT3_P36888	6863	835	D	D835Y	P36888_D835Y	A
P25092	S	840	I	/note=""S -> I (in DIAR6; activating mutation; exposure of the mutant receptor to its ligands results in markedly increased production of cyclic guanosine monophosphate; dbSNP:rs587776871)"" /evidence=""ECO:0000269|PubMed:22436048"" /id=""VAR_067724""	GUC2C	GUC2C_P25092	GUC2C_P25092_840	GUC2C_P25092	7223	840	S	S840I	P25092_S840I	A
P08631	Y	522	F	/note=""Y->F: Constitutively activated kinase, leading to cellular transformation."" /evidence=""ECO:0000269|PubMed:10092522, ECO:0000269|PubMed:11896602""	HCK	HCK_P08631	HCK_P08631_522	HCK_P08631	7139	522	Y	Y522F	P08631_Y522F	A
O14920	V	203	I	/note=""V -> I (in IMD15A; gain-of-function mutation resulting in increased activation of NF-kappa-B signaling pathway; dbSNP:rs1563340753)"" /evidence=""ECO:0000269|PubMed:30337470"" /id=""VAR_081275""	IKKB	IKKB_O14920	IKKB_O14920_203	IKKB_O14920	6962	203	V	V203I	O14920_V203I	A
O14920	K	171	E	/note=""K->E: Increased activation of NF-kappa-B signaling."" /evidence=""ECO:0000269|PubMed:30337470""	IKKB	IKKB_O14920	IKKB_O14920_171	IKKB_O14920	6859	171	K	K171E	O14920_K171E	A
P23458	V	658	F	/note=""V->F: Constitutively active. Increased receptor signaling pathway via JAK-STAT."" /evidence=""ECO:0000269|PubMed:16239216""	JAK1	JAK1_P23458	JAK1_P23458_658	JAK1_P23458	6249	658	V	V658F	P23458_V658F	A
Q9UQM7	P	212	Q	/note=""P -> Q (in MRD53; increased basal autophosphorylation)"" /evidence=""ECO:0000269|PubMed:29560374"" /id=""VAR_081160""	KCC2A	KCC2A_Q9UQM7	KCC2A_Q9UQM7_212	KCC2A_Q9UQM7	6983	212	P	P212Q	Q9UQM7_P212Q	A
P10721	D	816	F	/note=""D -> F (in MASTC; sporadic case; somatic mutation; requires 2 nucleotide substitutions; constitutively activated and is much more rapidly autophosphorylated than wild type)"" /evidence=""ECO:0000269|PubMed:9990072"" /id=""VAR_033133""	KIT	KIT_P10721	KIT_P10721_816	KIT_P10721	6863	816	D	D816F	P10721_D816F	A
P10721	D	816	H	/note=""D -> H (in a testicular tumor; seminoma; somatic mutation; constitutively activated; dbSNP:rs121913506)"" /evidence=""ECO:0000269|PubMed:10362788, ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:20147452"" /id=""VAR_033134""	KIT	KIT_P10721	KIT_P10721_816	KIT_P10721	6863	816	D	D816H	P10721_D816H	A
P10721	D	816	I	/note=""D -> I (in MASTC; somatic mutation; constitutively activated; requires 2 nucleotide substitutions; dbSNP:rs1057519709)"" /evidence=""ECO:0000269|PubMed:19865100"" /id=""VAR_081064""	KIT	KIT_P10721	KIT_P10721_816	KIT_P10721	6863	816	D	D816I	P10721_D816I	A
P10721	D	816	V	/note=""D -> V (in MASTSYS, MASTC and mast cell leukemia; somatic mutation; constitutively activated; loss of interaction with MPDZ; dbSNP:rs121913507)"" /evidence=""ECO:0000269|PubMed:11018522, ECO:0000269|PubMed:17595334, ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:19265199, ECO:0000269|PubMed:19865100, ECO:0000269|PubMed:21640708, ECO:0000269|PubMed:7691885, ECO:0000269|PubMed:9990072"" /id=""VAR_004109""	KIT	KIT_P10721	KIT_P10721_816	KIT_P10721	6863	816	D	D816V	P10721_D816V	A
P10721	D	816	Y	/note=""D -> Y (in MASTSYS and MASTC; also found in acute myeloid leukemia and a germ cell tumor of the testis; somatic mutation; constitutively activated; dbSNP:rs121913506)"" /evidence=""ECO:0000269|PubMed:16175573, ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19865100, ECO:0000269|PubMed:9657776, ECO:0000269|PubMed:9990072"" /id=""VAR_023828""	KIT	KIT_P10721	KIT_P10721_816	KIT_P10721	6863	816	D	D816Y	P10721_D816Y	A
P10721	N	822	I	/note=""N -> I (in MASTC; constitutively activated; dbSNP:rs993022333)"" /evidence=""ECO:0000269|PubMed:21689725"" /id=""VAR_081065""	KIT	KIT_P10721	KIT_P10721_822	KIT_P10721	6869	822	N	N822I	P10721_N822I	A
Q99683	S	966	A	/note=""S->A: Enhanced induction of apoptosis, increased kinase activity, and loss of YWHAG binding."" /evidence=""ECO:0000269|PubMed:10411906, ECO:0000269|PubMed:15094778""	M3K5	M3K5_Q99683	M3K5_Q99683_966	M3K5_Q99683	7153	966	S	S966A	Q99683_S966A	A
Q99683	S	1033	A	/note=""S->A: Enhanced induction of apoptosis and increased kinase activity."" /evidence=""ECO:0000269|PubMed:15094778""	M3K5	M3K5_Q99683	M3K5_Q99683_1033	M3K5_Q99683	7220	1033	S	S1033A	Q99683_S1033A	A
Q96L34	T	214	E	/note=""T->E: Mimicks phosphorylation state, leading to increased activity. Decreases mTORC1 activity."" /evidence=""ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:23184942""	MARK4	MARK4_Q96L34	MARK4_Q96L34_214	MARK4_Q96L34	6908	214	T	T214E	Q96L34_T214E	A
P36507	P	128	Q	/note=""P -> Q (in CFC4; results in increased kinase activity; dbSNP:rs267607230)"" /evidence=""ECO:0000269|PubMed:20358587"" /id=""VAR_069782""	MP2K2	MP2K2_P36507	MP2K2_P36507_128	NA	NA	NA	NA	P128Q	P36507_P128Q	A
P51955	T	170	E	/note=""T->E: Kinase activity increased by two fold."" /evidence=""ECO:0000269|PubMed:17197699""	NEK2	NEK2_P51955	NEK2_P51955_170	NEK2_P51955	6868	170	T	T170E	P51955_T170E	A
P51955	S	171	D	/note=""S->D: Kinase activity increased by two fold."" /evidence=""ECO:0000269|PubMed:17197699""	NEK2	NEK2_P51955	NEK2_P51955_171	NEK2_P51955	6869	171	S	S171D	P51955_S171D	A
P51955	T	175	E	/note=""T->E: Kinase activity increased by two fold."" /evidence=""ECO:0000269|PubMed:17197699""	NEK2	NEK2_P51955	NEK2_P51955_175	NEK2_P51955	6908	175	T	T175E	P51955_T175E	A
O96013	S	445	N	/note=""S->N: Approximately 30-fold increased autophosphorylation (constitutively active mutant)."" /evidence=""ECO:0000269|PubMed:11313478""	PAK4	PAK4_O96013	PAK4_O96013_445	PAK4_O96013	6820	445	S	S445N	O96013_S445N	A
O96013	S	474	E	/note=""S->E: Approximately 3-fold increased autophosphorylation."" /evidence=""ECO:0000269|PubMed:11313478""	PAK4	PAK4_O96013	PAK4_O96013_474	PAK4_O96013	6908	474	S	S474E	O96013_S474E	A
P16234	Y	555	C	/note=""Y -> C (in GISTPS; increased platelet-derived growth factor alpha-receptor activity; constitutively activated kinase; dbSNP:rs121908589)"" /evidence=""ECO:0000269|PubMed:17087943"" /id=""VAR_083158""	PGFRA	PGFRA_P16234	PGFRA_P16234_555	NA	NA	NA	NA	Y555C	P16234_Y555C	A
P16234	V	561	D	/note=""V -> D (in a GIST sample; constitutively activated kinase; dbSNP:rs121908586)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066462""	PGFRA	PGFRA_P16234	PGFRA_P16234_561	NA	NA	NA	NA	V561D	P16234_V561D	A
P16234	H	650	Q	/note=""H -> Q (in a hypereosinophilic syndrome sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:21224473"" /id=""VAR_066465""	PGFRA	PGFRA_P16234	PGFRA_P16234_650	NA	NA	NA	NA	H650Q	P16234_H650Q	A
P16234	N	659	K	/note=""N -> K (in GIST sample; constitutively activated kinase; dbSNP:rs1057519700)"" /evidence=""ECO:0000269|PubMed:15928335"" /id=""VAR_066466""	PGFRA	PGFRA_P16234	PGFRA_P16234_659	NA	NA	NA	NA	N659K	P16234_N659K	A
P16234	N	659	S	/note=""N -> S (in a hypereosinophilic syndrome sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:21224473"" /id=""VAR_066467""	PGFRA	PGFRA_P16234	PGFRA_P16234_659	NA	NA	NA	NA	N659S	P16234_N659S	A
P16234	R	748	G	/note=""R -> G (in a hypereosinophilic syndrome sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:21224473"" /id=""VAR_066469""	PGFRA	PGFRA_P16234	PGFRA_P16234_748	NA	NA	NA	NA	R748G	P16234_R748G	A
P16234	D	842de	l	/note=""Missing (in a GIST sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066470""	PGFRA	PGFRA_P16234	PGFRA_P16234_842de	NA	NA	NA	NA	D842del	P16234_D842del	A
P16234	I	843de	l	/note=""Missing (in a GIST sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066470""	PGFRA	PGFRA_P16234	PGFRA_P16234_843de	NA	NA	NA	NA	I843del	P16234_I843del	A
P16234	M	844de	l	/note=""Missing (in a GIST sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066470""	PGFRA	PGFRA_P16234	PGFRA_P16234_844de	NA	NA	NA	NA	M844del	P16234_M844del	A
P16234	H	845de	l	/note=""Missing (in a GIST sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066470""	PGFRA	PGFRA_P16234	PGFRA_P16234_845de	NA	NA	NA	NA	H845del	P16234_H845del	A
P16234	D	842	V	/note=""D -> V (in a GIST sample; imatinib resistant, constitutively activated kinase; dbSNP:rs121908585)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335, ECO:0000269|PubMed:20972453"" /id=""VAR_066471""	PGFRA	PGFRA_P16234	PGFRA_P16234_842	NA	NA	NA	NA	D842V	P16234_D842V	A
P16234	D	842	Y	/note=""D -> Y (in a GIST sample; imatinib sensitive, constitutively activated kinase; dbSNP:rs121913265)"" /evidence=""ECO:0000269|PubMed:15928335"" /id=""VAR_066472""	PGFRA	PGFRA_P16234	PGFRA_P16234_842	NA	NA	NA	NA	D842Y	P16234_D842Y	A
P16234	H	845de	l	/note=""Missing (in a GIST sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066473""	PGFRA	PGFRA_P16234	PGFRA_P16234_845de	NA	NA	NA	NA	H845del	P16234_H845del	A
P16234	D	846de	l	/note=""Missing (in a GIST sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066473""	PGFRA	PGFRA_P16234	PGFRA_P16234_846de	NA	NA	NA	NA	D846del	P16234_D846del	A
P16234	S	847de	l	/note=""Missing (in a GIST sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066473""	PGFRA	PGFRA_P16234	PGFRA_P16234_847de	NA	NA	NA	NA	S847del	P16234_S847del	A
P16234	N	848de	l	/note=""Missing (in a GIST sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066473""	PGFRA	PGFRA_P16234	PGFRA_P16234_848de	NA	NA	NA	NA	N848del	P16234_N848del	A
P16234	Y	849	S	/note=""Y -> S (in a hypereosinophilic syndrome sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:21224473"" /id=""VAR_066475""	PGFRA	PGFRA_P16234	PGFRA_P16234_849	NA	NA	NA	NA	Y849S	P16234_Y849S	A
P11309	H	68	Y	/note=""H->Y: Increased kinase activity."" /evidence=""ECO:0000269|PubMed:15808862""	PIM1	PIM1_P11309	PIM1_P11309_68	PIM1_P11309	6552	68	H	H68Y	P11309_H68Y	A
P04049	S	259	A	/note=""S -> A (in an ovarian serous carcinoma sample; somatic mutation; increased ERK activation; dbSNP:rs3730271)"" /evidence=""ECO:0000269|PubMed:16630891, ECO:0000269|PubMed:17344846"" /id=""VAR_041037""	RAF1	RAF1_P04049	RAF1_P04049_259	RAF1_P04049	6375	259	S	S259A	P04049_S259A	A
P04049	R	563	K	/note=""R->K: Loss of methylation. Increased stability and catalytic activity in response to EGF treatment."" /evidence=""ECO:0000269|PubMed:21917714""	RAF1	RAF1_P04049	RAF1_P04049_563	RAF1_P04049	7001	563	R	R563K	P04049_R563K	A
Q13546	D	324	H	/note=""D -> H (in AIEFL; prevents cleavage by CASP8; increased kinase activity; increased inflammatory response)"" /evidence=""ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:31827281"" /id=""VAR_083518""	RIPK1	RIPK1_Q13546	RIPK1_Q13546_324	RIPK1_Q13546	7168	324	D	D324H	Q13546_D324H	A
Q13546	D	324	V	/note=""D -> V (in AIEFL; prevents cleavage by CASP8; increased kinase activity; increased inflammatory response)"" /evidence=""ECO:0000269|PubMed:31827280"" /id=""VAR_084135""	RIPK1	RIPK1_Q13546	RIPK1_Q13546_324	RIPK1_Q13546	7168	324	D	D324V	Q13546_D324V	A
Q9HBY8	S	356	D	/note=""S->D: Increased activation."" /evidence=""ECO:0000269|PubMed:10548550""	SGK2	SGK2_Q9HBY8	SGK2_Q9HBY8_356	SGK2_Q9HBY8	7188	356	S	S356D	Q9HBY8_S356D	A
Q96BR1	S	486	D	/note=""S->D: Increased activation."" /evidence=""ECO:0000269|PubMed:10548550""	SGK3	SGK3_Q96BR1	SGK3_Q96BR1_486	SGK3_Q96BR1	7191	486	S	S486D	Q96BR1_S486D	A
Q02763	R	849	W	/note=""R -> W (in VMCM; increased ligand-independent autophosphorylation and kinase activation; no effect on location at membrane; dbSNP:rs80338908)"" /evidence=""ECO:0000269|PubMed:10369874, ECO:0000269|PubMed:19079259, ECO:0000269|PubMed:19888299, ECO:0000269|PubMed:8980225"" /id=""VAR_006352""	TIE2	TIE2_Q02763	TIE2_Q02763_849	TIE2_Q02763	6534	849	R	R849W	Q02763_R849W	A
Q02763	Y	897	C	/note=""Y -> C (in VMCM; increased ligand-independent autophosphorylation and kinase activation; dbSNP:rs80338909)"" /evidence=""ECO:0000269|PubMed:19888299"" /id=""VAR_066606""	TIE2	TIE2_Q02763	TIE2_Q02763_897	TIE2_Q02763	6634	897	Y	Y897C	Q02763_Y897C	A
Q02763	Y	897	H	/note=""Y -> H (found in a patient with solitary sporadic venous malformations; increased ligand-independent autophosphorylation)"" /evidence=""ECO:0000269|PubMed:19079259"" /id=""VAR_078050""	TIE2	TIE2_Q02763	TIE2_Q02763_897	TIE2_Q02763	6634	897	Y	Y897H	Q02763_Y897H	A
Q02763	Y	897	S	/note=""Y -> S (in VMCM; also found in a patient with solitary sporadic venous malformations; increased ligand- independent autophosphorylation and kinase activation; dbSNP:rs80338909)"" /evidence=""ECO:0000269|PubMed:10369874, ECO:0000269|PubMed:19079259, ECO:0000269|PubMed:19888299"" /id=""VAR_008716""	TIE2	TIE2_Q02763	TIE2_Q02763_897	TIE2_Q02763	6634	897	Y	Y897S	Q02763_Y897S	A
Q02763	L	914	F	/note=""L -> F (found in patients with solitary and multiple sporadic venous malformations; increased ligand-independent autophosphorylation; novel location at endoplasmic reticulum and Golgi apparatus; partially retained at endoplasmic reticulum and Golgi apparatus)"" /evidence=""ECO:0000269|PubMed:19079259"" /id=""VAR_078051""	TIE2	TIE2_Q02763	TIE2_Q02763_914	TIE2_Q02763	6652	914	L	L914F	Q02763_L914F	A
Q02763	R	915	C	/note=""R -> C (found in a patient with solitary sporadic venous malformations; increased ligand-independent autophosphorylation)"" /evidence=""ECO:0000269|PubMed:19079259"" /id=""VAR_078052""	TIE2	TIE2_Q02763	TIE2_Q02763_915	TIE2_Q02763	6653	915	R	R915C	Q02763_R915C	A
Q02763	R	915	H	/note=""R -> H (in VMCM; strongly increased ligand- independent autophosphorylation and kinase activation; dbSNP:rs387906745)"" /evidence=""ECO:0000269|PubMed:19888299"" /id=""VAR_066607""	TIE2	TIE2_Q02763	TIE2_Q02763_915	TIE2_Q02763	6653	915	R	R915H	Q02763_R915H	A
Q02763	S	917	I	/note=""S -> I (found in a patient with solitary sporadic venous malformations; increased ligand-independent autophosphorylation)"" /evidence=""ECO:0000269|PubMed:19079259"" /id=""VAR_078054""	TIE2	TIE2_Q02763	TIE2_Q02763_917	TIE2_Q02763	6655	917	S	S917I	Q02763_S917I	A
Q02763	R	918	C	/note=""R -> C (in VMCM; strongly increased ligand- independent autophosphorylation and kinase activation)"" /evidence=""ECO:0000269|PubMed:19888299"" /id=""VAR_066608""	TIE2	TIE2_Q02763	TIE2_Q02763_918	TIE2_Q02763	6656	918	R	R918C	Q02763_R918C	A
Q02763	V	919	L	/note=""V -> L (in VMCM; increased ligand-independent autophosphorylation and kinase activation)"" /evidence=""ECO:0000269|PubMed:19888299"" /id=""VAR_066609""	TIE2	TIE2_Q02763	TIE2_Q02763_919	TIE2_Q02763	6657	919	V	V919L	Q02763_V919L	A
Q02763	A	925	S	/note=""A -> S (in VMCM; increased ligand-independent autophosphorylation and kinase activation)"" /evidence=""ECO:0000269|PubMed:19888299"" /id=""VAR_066610""	TIE2	TIE2_Q02763	TIE2_Q02763_925	TIE2_Q02763	6664	925	A	A925S	Q02763_A925S	A
Q02763	K	1100	N	/note=""K -> N (in VMCM; strongly increased ligand- independent autophosphorylation and kinase activation)"" /evidence=""ECO:0000269|PubMed:19888299"" /id=""VAR_066611""	TIE2	TIE2_Q02763	TIE2_Q02763_1100	TIE2_Q02763	7135	1100	K	K1100N	Q02763_K1100N	A
P43403	W	131	A	/note=""W->A: Increased constitutive kinase activity."" /evidence=""ECO:0000269|PubMed:17512407""	ZAP70	ZAP70_P43403	ZAP70_P43403_131	ZAP70_P43403	6256	131	W	W131A	P43403_W131A	A
P43403	L	133	A	/note=""L->A: Increased constitutive kinase activity."" /evidence=""ECO:0000269|PubMed:17512407""	ZAP70	ZAP70_P43403	ZAP70_P43403_133	ZAP70_P43403	6258	133	L	L133A	P43403_L133A	A
P43403	A	141	E	/note=""A->E: Increased constitutive kinase activity."" /evidence=""ECO:0000269|PubMed:17512407""	ZAP70	ZAP70_P43403	ZAP70_P43403_141	ZAP70_P43403	6266	141	A	A141E	P43403_A141E	A
P43403	S	144	A	/note=""S->A: Increased kinase activity after activation by LCK."" /evidence=""ECO:0000269|PubMed:17512407""	ZAP70	ZAP70_P43403	ZAP70_P43403_144	ZAP70_P43403	6269	144	S	S144A	P43403_S144A	A
P43403	Q	145	A	/note=""Q->A: Increased kinase activity after activation by LCK."" /evidence=""ECO:0000269|PubMed:17512407""	ZAP70	ZAP70_P43403	ZAP70_P43403_145	ZAP70_P43403	6270	145	Q	Q145A	P43403_Q145A	A
P43403	P	147	A	/note=""P->A: Increased kinase activity after activation by LCK."" /evidence=""ECO:0000269|PubMed:17512407""	ZAP70	ZAP70_P43403	ZAP70_P43403_147	ZAP70_P43403	6272	147	P	P147A	P43403_P147A	A
P43403	V	314	A	/note=""V->A: Increased constitutive kinase activity.""	ZAP70	ZAP70_P43403	ZAP70_P43403_314	ZAP70_P43403	6439	314	V	V314A	P43403_V314A	A
P43403	Y	597	A	/note=""Y->A: Increased kinase activity after activation by LCK."" /evidence=""ECO:0000269|PubMed:17512407""	ZAP70	ZAP70_P43403	ZAP70_P43403_597	ZAP70_P43403	7135	597	Y	Y597A	P43403_Y597A	A
P43403	Y	598	A	/note=""Y->A: Increased kinase activity after activation by LCK."" /evidence=""ECO:0000269|PubMed:17512407""	ZAP70	ZAP70_P43403	ZAP70_P43403_598	ZAP70_P43403	7136	598	Y	Y598A	P43403_Y598A	A
P15056	K	483	S	/note=""K->S: Reduces kinase activity with MAP2K1."" /evidence=""ECO:0000269|PubMed:21441910""	BRAF	BRAF_P15056	BRAF_P15056_483	BRAF_P15056	6551	483	K	K483S	P15056_K483S	D
Q8IWQ3	T	260	A	/note=""T->A: Decreased phosphorylation. Nearly abolishes stimulation of insulin secretion."" /evidence=""ECO:0000269|PubMed:16870137, ECO:0000269|PubMed:22669945""	BRSK2	BRSK2_Q8IWQ3	BRSK2_Q8IWQ3_260	BRSK2_Q8IWQ3	7108	260	T	T260A	Q8IWQ3_T260A	D
P24941	K	9	F	/note=""K->F: Reduced phosphorylation by CAK."" /evidence=""ECO:0000269|PubMed:17373709""	CDK2	CDK2_P24941	CDK2_P24941_9	CDK2_P24941	6473	9	K	K9F	P24941_K9F	D
P24941	K	88	E	/note=""KK->EV: Reduced phosphorylation by CAK."" /evidence=""ECO:0000269|PubMed:17373709""	CDK2	CDK2_P24941	CDK2_P24941_88	CDK2_P24941	6649	88	K	K88E	P24941_K88E	D
P24941	K	89	V	/note=""KK->EV: Reduced phosphorylation by CAK."" /evidence=""ECO:0000269|PubMed:17373709""	CDK2	CDK2_P24941	CDK2_P24941_89	CDK2_P24941	6650	89	K	K89V	P24941_K89V	D
P24941	L	166	R	/note=""L->R: Reduced phosphorylation by CAK and reduced kinase activity."" /evidence=""ECO:0000269|PubMed:17373709""	CDK2	CDK2_P24941	CDK2_P24941_166	CDK2_P24941	6919	166	L	L166R	P24941_L166R	D
O96017	H	371	Y	/note=""H -> Y (confers a moderate risk of breast cancer; partially reduces kinase activity; dbSNP:rs531398630)"" /evidence=""ECO:0000269|PubMed:21618645"" /id=""VAR_066012""	CHK2	CHK2_O96017	CHK2_O96017_371	CHK2_O96017	6854	371	H	H371Y	O96017_H371Y	D
P07333	Y	809	F	/note=""Y->F: Reduced kinase activity. Reduced interaction with SRC, FYN and YES1."" /evidence=""ECO:0000269|PubMed:7681396""	CSF1R	CSF1R_P07333	CSF1R_P07333_809	CSF1R_P07333	6870	809	Y	Y809F	P07333_Y809F	D
P53355	S	308	D	/note=""S->D: Reduced Ca(2+)-calmodulin binding and Ca(2+)- calmodulin-independent kinase activity. Decreases apoptotic activity."" /evidence=""ECO:0000269|PubMed:11579085""	DAPK1	DAPK1_P53355	DAPK1_P53355_308	DAPK1_P53355	7157	308	S	S308D	P53355_S308D	D
O43293	T	112	M	/note=""T -> M (in a colorectal adenocarcinoma sample; somatic mutation; greatly reduces kinase activity, increases cell proliferation and cell survival)"" /evidence=""ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:21487036"" /id=""VAR_040438""	DAPK3	DAPK3_O43293	DAPK3_O43293_112	DAPK3_O43293	6680	112	T	T112M	O43293_T112M	D
O43293	D	161	N	/note=""D -> N (in an ovarian mucinous carcinoma sample; somatic mutation; greatly reduces kinase activity, increases cell proliferation and cell survival)"" /evidence=""ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:21487036"" /id=""VAR_040439""	DAPK3	DAPK3_O43293	DAPK3_O43293_161	DAPK3_O43293	6851	161	D	D161N	O43293_D161N	D
O43293	P	216	S	/note=""P -> S (in a lung neuroendocrine carcinoma sample; somatic mutation; greatly reduces kinase activity, increases cell proliferation, cell adhesion and cell survival)"" /evidence=""ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:21487036"" /id=""VAR_040440""	DAPK3	DAPK3_O43293	DAPK3_O43293_216	DAPK3_O43293	6983	216	P	P216S	O43293_P216S	D
O43293	T	180	A	/note=""T->A: Greatly reduced kinase activity."" /evidence=""ECO:0000269|PubMed:21487036""	DAPK3	DAPK3_O43293	DAPK3_O43293_180	DAPK3_O43293	6915	180	T	T180A	O43293_T180A	D
Q13627	Y	321	F	/note=""Y->F: Mildly reduces kinase activity. Does not abolish autophosphorylation on tyrosine residues."" /evidence=""ECO:0000269|PubMed:23665168""	DYR1A	DYR1A_Q13627	DYR1A_Q13627_321	DYR1A_Q13627	6912	321	Y	Y321F	Q13627_Y321F	D
P00533	L	688	A	/note=""L->A: Strongly reduced phosphorylation."" /evidence=""ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760""	EGFR	EGFR_P00533	EGFR_P00533_688	EGFR_P00533	6444	688	L	L688A	P00533_L688A	D
P00533	V	689	A	/note=""V->A: Reduced autophosphorylation."" /evidence=""ECO:0000269|PubMed:19560417""	EGFR	EGFR_P00533	EGFR_P00533_689	EGFR_P00533	6445	689	V	V689A	P00533_V689A	D
P00533	E	690	A	/note=""E->A: Reduced phosphorylation."" /evidence=""ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760""	EGFR	EGFR_P00533	EGFR_P00533_690	EGFR_P00533	6446	690	E	E690A	P00533_E690A	D
P00533	L	692	A	/note=""L->A,P: Strongly reduced phosphorylation."" /evidence=""ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760""	EGFR	EGFR_P00533	EGFR_P00533_692	EGFR_P00533	6448	692	L	L692A	P00533_L692A	D
P00533	T	693	D	/note=""T->D: Strongly reduced phosphorylation."" /evidence=""ECO:0000269|PubMed:19560417""	EGFR	EGFR_P00533	EGFR_P00533_693	EGFR_P00533	6449	693	T	T693D	P00533_T693D	D
P00533	P	694	A	/note=""P->A: Strongly reduced phosphorylation."" /evidence=""ECO:0000269|PubMed:19560417""	EGFR	EGFR_P00533	EGFR_P00533_694	EGFR_P00533	6450	694	P	P694A	P00533_P694A	D
P00533	P	699	A	/note=""P->A: Reduced phosphorylation."" /evidence=""ECO:0000269|PubMed:19560417""	EGFR	EGFR_P00533	EGFR_P00533_699	EGFR_P00533	6455	699	P	P699A	P00533_P699A	D
P00533	D	974	A	/note=""D->A: Strongly reduced phosphorylation.""	EGFR	EGFR_P00533	EGFR_P00533_974	EGFR_P00533	7134	974	D	D974A	P00533_D974A	D
P00533	R	977	A	/note=""R->A: Reduced phosphorylation."" /evidence=""ECO:0000269|PubMed:19563760""	EGFR	EGFR_P00533	EGFR_P00533_977	EGFR_P00533	7137	977	R	R977A	P00533_R977A	D
P21860	K	742	M	/note=""K->M: Strongly reduced autophosphorylation."" /evidence=""ECO:0000269|PubMed:20351256""	ERBB3	ERBB3_P21860	ERBB3_P21860_742	ERBB3_P21860	6551	742	K	K742M	P21860_K742M	D
P21860	Y	868	E	/note=""Y->E: Strongly reduced tyrosine phosphorylation."" /evidence=""ECO:0000269|PubMed:20351256""	ERBB3	ERBB3_P21860	ERBB3_P21860_868	ERBB3_P21860	6906	868	Y	Y868E	P21860_Y868E	D
Q15303	R	927	Q	/note=""R -> Q (in ALS19; reduces autophosphorylation upon NRG1 stimulation; dbSNP:rs397514262)"" /evidence=""ECO:0000269|PubMed:24119685"" /id=""VAR_070810""	ERBB4	ERBB4_Q15303	ERBB4_Q15303_927	ERBB4_Q15303	7007	927	R	R927Q	Q15303_R927Q	D
Q15303	R	1275	W	/note=""R -> W (in ALS19; reduces autophosphorylation upon NRG1 stimulation; dbSNP:rs397514263)"" /evidence=""ECO:0000269|PubMed:24119685"" /id=""VAR_070811""	ERBB4	ERBB4_Q15303	ERBB4_Q15303_1275	ERBB4_Q15303	7428	1275	R	R1275W	Q15303_R1275W	D
Q15303	L	710	N	/note=""L->N: Strongly reduced autophosphorylation."" /evidence=""ECO:0000269|PubMed:18287036""	ERBB4	ERBB4_Q15303	ERBB4_Q15303_710	ERBB4_Q15303	6458	710	L	L710N	Q15303_L710N	D
Q15303	M	766	R	/note=""M->R: Strongly reduced autophosphorylation."" /evidence=""ECO:0000269|PubMed:18287036""	ERBB4	ERBB4_Q15303	ERBB4_Q15303_766	ERBB4_Q15303	6573	766	M	M766R	Q15303_M766R	D
Q15303	L	864	R	/note=""L->R: Strongly reduced autophosphorylation."" /evidence=""ECO:0000269|PubMed:18287036""	ERBB4	ERBB4_Q15303	ERBB4_Q15303_864	ERBB4_Q15303	6854	864	L	L864R	Q15303_L864R	D
Q14289	Y	881	F	/note=""Y->F: Loss of phosphorylation site. Strongly reduced interaction with GRB2."" /evidence=""ECO:0000269|PubMed:20521079""	FAK2	FAK2_Q14289	FAK2_Q14289_881	FAK2_Q14289	7329	881	Y	Y881F	Q14289_Y881F	D
P07332	R	483	M	/note=""R->M: Abolishes pTyr binding. Abolishes association with microtubules. Abolishes autophosphorylation. Reduced kinase activity."" /evidence=""ECO:0000269|PubMed:15485904, ECO:0000269|PubMed:18775312""	FES	FES_P07332	FES_P07332_483	FES_P07332	6387	483	R	R483M	P07332_R483M	D
P07332	M	704	V	/note=""M->V: Reduced autophosphorylation and strongly reduced kinase activity."" /evidence=""ECO:0000269|PubMed:15867340, ECO:0000269|PubMed:16455651""	FES	FES_P07332	FES_P07332_704	FES_P07332	6854	704	M	M704V	P07332_M704V	D
P07332	Y	713	F	/note=""Y->F: Reduces kinase activity by over 90%."" /evidence=""ECO:0000269|PubMed:7687763""	FES	FES_P07332	FES_P07332_713	FES_P07332	6869	713	Y	Y713F	P07332_Y713F	D
P07332	V	743	M	/note=""V->M: Strongly reduced autophosphorylation and kinase activity."" /evidence=""ECO:0000269|PubMed:15867340, ECO:0000269|PubMed:16455651""	FES	FES_P07332	FES_P07332_743	FES_P07332	6964	743	V	V743M	P07332_V743M	D
P07332	S	759	F	/note=""S->F: Reduced autophosphorylation and strongly reduced kinase activity."" /evidence=""ECO:0000269|PubMed:15867340, ECO:0000269|PubMed:16455651""	FES	FES_P07332	FES_P07332_759	FES_P07332	6982	759	S	S759F	P07332_S759F	D
P21802	M	391	R	/note=""M -> R (in BBDS; the mutation selectively reduces plasma-membrane levels of the protein and markedly diminishes the receptor's responsiveness to extracellular FGF; dbSNP:rs387906677)"" /evidence=""ECO:0000269|PubMed:22387015"" /id=""VAR_067978""	FGFR2	FGFR2_P21802	FGFR2_P21802_391	FGFR2_P21802	6375	391	M	M391R	P21802_M391R	D
P21802	A	628	T	/note=""A -> T (in LADDS; strongly reduced kinase activity; dbSNP:rs121918509)"" /evidence=""ECO:0000269|PubMed:16501574"" /id=""VAR_029884""	FGFR2	FGFR2_P21802	FGFR2_P21802_628	FGFR2_P21802	6817	628	A	A628T	P21802_A628T	D
P22607	Y	724	F	/note=""Y->F: Strongly reduced kinase activity. Strongly reduced mitogen activity."" /evidence=""ECO:0000269|PubMed:11294897""	FGFR3	FGFR3_P22607	FGFR3_P22607_724	FGFR3_P22607	7092	724	Y	Y724F	P22607_Y724F	D
P08631	Y	411	A	/note=""Y->A: Reduced catalytic activity and higher affinity for target peptides."" /evidence=""ECO:0000269|PubMed:10644735""	HCK	HCK_P08631	HCK_P08631_411	HCK_P08631	6906	411	Y	Y411A	P08631_Y411A	D
P08069	Y	980	F	/note=""Y->F: Reduces tyrosine phosphorylation. Abolishes interaction with IRS1 and SHC1. Does not abolish interaction with PIK3R1, nor with GRB10."" /evidence=""ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:7541045""	IGF1R	IGF1R_P08069	IGF1R_P08069_980	IGF1R_P08069	6446	980	Y	Y980F	P08069_Y980F	D
P08069	K	1033	A	/note=""K->A: Kinase inactive. Abolishes tyrosine phosphorylation and abolishes interaction with IRS1, SHC1 and PIK3R1."" /evidence=""ECO:0000269|PubMed:7541045""	IGF1R	IGF1R_P08069	IGF1R_P08069_1033	IGF1R_P08069	6551	1033	K	K1033A	P08069_K1033A	D
P06213	K	1057	A	/note=""K->A: Abolishes the kinase activity and abolishes interaction with IRS1, SHC1, GRB7 and PIK3R1."" /evidence=""ECO:0000269|PubMed:10803466, ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849""	INSR	INSR_P06213	INSR_P06213_1057	INSR_P06213	6551	1057	K	K1057A	P06213_K1057A	D
P51617	T	209	A	/note=""T->A: Completely abolishes auto-phosphorylation in the kinase domain."" /evidence=""ECO:0000269|PubMed:14625308""	IRAK1	IRAK1_P51617	IRAK1_P51617_209	IRAK1_P51617	6463	209	T	T209A	P51617_T209A	D
Q9Y616	S	110	A	/note=""S->A: Abolishes phosphorylation. Abolishes interaction with PIN1. Reduces protein stability."" /evidence=""ECO:0000269|PubMed:29686383""	IRAK3	IRAK3_Q9Y616	IRAK3_Q9Y616_110	IRAK3_Q9Y616	6412	110	S	S110A	Q9Y616_S110A	D
P48730	T	44	A	/note=""T -> A (in FASPS2; strongly reduces kinase activity; dbSNP:rs104894561)"" /evidence=""ECO:0000269|PubMed:15800623, ECO:0000269|PubMed:23636092"" /id=""VAR_029075""	KC1D	KC1D_P48730	KC1D_P48730_44	KC1D_P48730	6557	44	T	T44A	P48730_T44A	D
P48730	H	46	R	/note=""H -> R (in FASPS2; strongly reduces kinase activity; dbSNP:rs397514693)"" /evidence=""ECO:0000269|PubMed:23636092"" /id=""VAR_069801""	KC1D	KC1D_P48730	KC1D_P48730_46	KC1D_P48730	6559	46	H	H46R	P48730_H46R	D
P10721	R	381	A	/note=""R->A: Reduces autophosphorylation in response to KITLG/SCF."" /evidence=""ECO:0000269|PubMed:17662946""	KIT	KIT_P10721	KIT_P10721_381	KIT_P10721	6257	381	R	R381A	P10721_R381A	D
P10721	E	386	A	/note=""E->A: Reduces autophosphorylation in response to KITLG/SCF."" /evidence=""ECO:0000269|PubMed:17662946""	KIT	KIT_P10721	KIT_P10721_386	KIT_P10721	6262	386	E	E386A	P10721_E386A	D
P53667	T	508	V	/note=""T->V: Reduces kinase activity."" /evidence=""ECO:0000269|PubMed:10196227, ECO:0000269|PubMed:10652353""	LIMK1	LIMK1_P53667	LIMK1_P53667_508	LIMK1_P53667	6908	508	T	T508V	P53667_T508V	D
P07948	Y	397	F	/note=""Y->F: Strongly reduced kinase activity."" /evidence=""ECO:0000269|PubMed:16920712""	LYN	LYN_P07948	LYN_P07948_397	LYN_P07948	6906	397	Y	Y397F	P07948_Y397F	D
Q16584	K	144	A	/note=""K->A: Greatly reduced autophosphorylation activity."" /evidence=""ECO:0000269|PubMed:11053428, ECO:0000269|PubMed:8195146""	M3K11	M3K11_Q16584	M3K11_Q16584_144	M3K11_Q16584	6551	144	K	K144A	Q16584_K144A	D
Q16584	E	164	A	/note=""E->A: Greatly reduced autophosphorylation activity."" /evidence=""ECO:0000269|PubMed:8195146""	M3K11	M3K11_Q16584	M3K11_Q16584_164	M3K11_Q16584	6575	164	E	E164A	Q16584_E164A	D
Q16584	T	277	A	/note=""T->A: Severely reduced autophosphorylation activity. Prevents phosphorylation of SAPK and MAPK14."" /evidence=""ECO:0000269|PubMed:11053428""	M3K11	M3K11_Q16584	M3K11_Q16584_277	M3K11_Q16584	6867	277	T	T277A	Q16584_T277A	D
Q16584	S	281	A	/note=""S->A: Reduced autophosphorylation activity. Reduced activation of SAPK and MAPK14."" /evidence=""ECO:0000269|PubMed:11053428""	M3K11	M3K11_Q16584	M3K11_Q16584_281	M3K11_Q16584	6908	281	S	S281A	Q16584_S281A	D
P80192	T	304	A	/note=""T->A: Reduces threonine phosphorylation. Impairs JNK activation."" /evidence=""ECO:0000269|PubMed:15610029""	M3K9	M3K9_P80192	M3K9_P80192_304	M3K9_P80192	6867	304	T	T304A	P80192_T304A	D
P49137	K	93	R	/note=""K->R: Kinase defective mutant, abolishes activity."" /evidence=""ECO:0000269|PubMed:14517288""	MAPK2	MAPK2_P49137	MAPK2_P49137_93	MAPK2_P49137	6551	93	K	K93R	P49137_K93R	D
P49137	D	207	A	/note=""D->A: Kinase defective mutant, abolishes activity."" /evidence=""ECO:0000269|PubMed:8846784""	MAPK2	MAPK2_P49137	MAPK2_P49137_207	MAPK2_P49137	6851	207	D	D207A	P49137_D207A	D
Q8IW41	K	51	M	/note=""K->M: Kinase defective mutant, abolishes activity."" /evidence=""ECO:0000269|PubMed:12808055""	MAPK5	MAPK5_Q8IW41	MAPK5_Q8IW41_51	MAPK5_Q8IW41	6551	51	K	K51M	Q8IW41_K51M	D
Q9HBH9	D	228	G	/note=""D->G: Reduced phosphorylation."" /evidence=""ECO:0000269|PubMed:16917500""	MKNK2	MKNK2_Q9HBH9	MKNK2_Q9HBH9_228	MKNK2_Q9HBH9	6853	228	D	D228G	Q9HBH9_D228G	D
Q02750	K	97	A	/note=""K->A: Loss of catalytic activity. Strongly reduces phosphorylation upon UV irradiation."" /evidence=""ECO:0000269|PubMed:20956560""	MP2K1	MP2K1_Q02750	MP2K1_Q02750_97	NA	NA	NA	NA	K97A	Q02750_K97A	D
O15146	I	575	T	/note=""I -> T (in FADS1; reduces agrin-dependent AChR aggregation and tyrosine kinase activity in developing neuromuscular junction; dbSNP:rs751889864)"" /evidence=""ECO:0000269|PubMed:25537362"" /id=""VAR_072787""	MUSK	MUSK_O15146	MUSK_O15146_575	MUSK_O15146	6466	575	I	I575T	O15146_I575T	D
Q15746	A	1754	T	/note=""A -> T (in AAT7; 4-fold reduced affinity for calmodulin; decreased kinase activity compared to wild-type protein)"" /evidence=""ECO:0000269|PubMed:21055718"" /id=""VAR_065576""	MYLK	MYLK_Q15746	MYLK_Q15746_1754	MYLK_Q15746	7159	1754	A	A1754T	Q15746_A1754T	D
Q15746	S	1759	P	/note=""S -> P (in AAT7; 7-fold reduced affinity for calmodulin; 6-fold decreased Vmax; dbSNP:rs387906781)"" /evidence=""ECO:0000269|PubMed:21055718"" /id=""VAR_065577""	MYLK	MYLK_Q15746	MYLK_Q15746_1759	MYLK_Q15746	7164	1759	S	S1759P	Q15746_S1759P	D
P04629	D	596	N	/note=""D -> N (in CIPA; abolishes autophosphorylation)"" /evidence=""ECO:0000269|PubMed:28177573"" /id=""VAR_079404""	NTRK1	NTRK1_P04629	NTRK1_P04629_596	NTRK1_P04629	6646	596	D	D596N	P04629_D596N	D
P09619	Y	857	F	/note=""Y->F: Reduces kinase activity. No effect on interaction with GRB10. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity."" /evidence=""ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1653029, ECO:0000269|PubMed:20494825""	PGFRB	PGFRB_P09619	PGFRB_P09619_857	PGFRB_P09619	6870	857	Y	Y857F	P09619_Y857F	D
Q9BXM7	G	386	A	/note=""G -> A (in PARK6; abolishes kinase activity)"" /evidence=""ECO:0000269|PubMed:16401616, ECO:0000269|PubMed:24784582"" /id=""VAR_062776""	PINK1	PINK1_Q9BXM7	PINK1_Q9BXM7_386	PINK1_Q9BXM7	6853	386	G	G386A	Q9BXM7_G386A	D
Q16513	T	816	A	/note=""T->A: Reduces catalytic activity."" /evidence=""ECO:0000269|PubMed:18835241""	PKN2	PKN2_Q16513	PKN2_Q16513_816	PKN2_Q16513	6908	816	T	T816A	Q16513_T816A	D
Q16513	F	977	A	/note=""F->A,L: Abolishes interaction with PDPK1 and prevents the phosphorylation of AKT1 at 'Ser-473'. Reduces catalytic activity by 90%."" /evidence=""ECO:0000269|PubMed:10226025, ECO:0000269|PubMed:18835241""	PKN2	PKN2_Q16513	PKN2_Q16513_977	PKN2_Q16513	7185	977	F	F977A	Q16513_F977A	D
Q16513	F	977	W	/note=""F->W,Y: Reduces catalytic activity by 50%."" /evidence=""ECO:0000269|PubMed:10226025, ECO:0000269|PubMed:18835241""	PKN2	PKN2_Q16513	PKN2_Q16513_977	PKN2_Q16513	7185	977	F	F977W	Q16513_F977W	D
Q16513	Y	979	A	/note=""Y->A: Reduces catalytic activity by 50%."" /evidence=""ECO:0000269|PubMed:10226025, ECO:0000269|PubMed:18835241""	PKN2	PKN2_Q16513	PKN2_Q16513_979	PKN2_Q16513	7187	979	Y	Y979A	Q16513_Y979A	D
Q16513	Y	979	F	/note=""Y->F,L,W: Reduces catalytic activity by 25%."" /evidence=""ECO:0000269|PubMed:10226025, ECO:0000269|PubMed:18835241""	PKN2	PKN2_Q16513	PKN2_Q16513_979	PKN2_Q16513	7187	979	Y	Y979F	Q16513_Y979F	D
P53350	T	210	V	/note=""T->V: Reduced catalytic activity, but no effect on affinity for ATP."" /evidence=""ECO:0000269|PubMed:12207013, ECO:0000269|PubMed:12447691, ECO:0000269|PubMed:17461553, ECO:0000269|PubMed:18615013, ECO:0000269|PubMed:19160488""	PLK1	PLK1_P53350	PLK1_P53350_210	PLK1_P53350	6908	210	T	T210V	P53350_T210V	D
P53350	W	414	F	/note=""W->F: Abolishes interaction with CDC25C and reduces centrosomal localization."" /evidence=""ECO:0000269|PubMed:17307877""	PLK1	PLK1_P53350	PLK1_P53350_414	PLK1_P53350	7233	414	W	W414F	P53350_W414F	D
Q9H4B4	K	91	R	/note=""K->R: Kinase defective mutant, abolishes activity."" /evidence=""ECO:0000269|PubMed:11447225, ECO:0000269|PubMed:14980500, ECO:0000269|PubMed:17804415, ECO:0000269|PubMed:19103756, ECO:0000269|PubMed:19490146, ECO:0000269|PubMed:20889502, ECO:0000269|PubMed:20940307""	PLK3	PLK3_Q9H4B4	PLK3_Q9H4B4_91	PLK3_Q9H4B4	6551	91	K	K91R	Q9H4B4_K91R	D
Q9H4B4	D	203	A	/note=""D->A: Kinase defective mutant, abolishes activity."" /evidence=""ECO:0000269|PubMed:11156373""	PLK3	PLK3_Q9H4B4	PLK3_Q9H4B4_203	PLK3_Q9H4B4	6851	203	D	D203A	Q9H4B4_D203A	D
P04049	D	486	N	/note=""D -> N (in NS5; has reduced or absent kinase activity; dbSNP:rs80338798)"" /evidence=""ECO:0000269|PubMed:17603483"" /id=""VAR_037817""	RAF1	RAF1_P04049	RAF1_P04049_486	RAF1_P04049	6851	486	D	D486N	P04049_D486N	D
P04049	T	491	I	/note=""T -> I (in NS5; has reduced or absent kinase activity; dbSNP:rs80338799)"" /evidence=""ECO:0000269|PubMed:17603483"" /id=""VAR_037818""	RAF1	RAF1_P04049	RAF1_P04049_491	RAF1_P04049	6859	491	T	T491I	P04049_T491I	D
P04049	L	603	P	/note=""L -> P (in CMD1NN; shows impaired kinase activity and reduced MAPK3 activation with this mutation; dbSNP:rs587777586)"" /evidence=""ECO:0000269|PubMed:24777450"" /id=""VAR_071847""	RAF1	RAF1_P04049	RAF1_P04049_603	RAF1_P04049	7119	603	L	L603P	P04049_L603P	D
Q13546	S	536	C	/note=""S->C: Strongly reduced homodimerization and interaction with RIPK3."" /evidence=""ECO:0000269|PubMed:29681455""	RIPK1	RIPK1_Q13546	RIPK1_Q13546_536	RIPK1_Q13546	7380	536	S	S536C	Q13546_S536C	D
O43353	Y	381	A	/note=""Y->A: Prevents phosphorylation. Reduces serine and threonine phosphorylation of ARHGEF2.""	RIPK2	RIPK2_O43353	RIPK2_O43353_381	RIPK2_O43353	7218	381	Y	Y381A	O43353_Y381A	D
Q05823	R	462	Q	/note=""R -> Q (risk factor for prostate cancer; reduced enzymatic activity; dbSNP:rs486907)"" /evidence=""ECO:0000269|PubMed:11799394, ECO:0000269|PubMed:11941539, ECO:0000269|PubMed:12415269, ECO:0000269|PubMed:17344846"" /id=""VAR_012056""	RN5A	RN5A_Q05823	RN5A_Q05823_462	RN5A_Q05823	6782	462	R	R462Q	Q05823_R462Q	D
Q01973	R	736	T	/note=""R -> T (in DFNB108; impairs plasma membrane location; abolishes downstream NFkB activation; dbSNP:rs1553163562)"" /evidence=""ECO:0000269|PubMed:27162350"" /id=""VAR_079530""	ROR1	ROR1_Q01973	ROR1_Q01973_736	ROR1_Q01973	7106	736	R	R736T	Q01973_R736T	D
P57059	T	182	A	/note=""T->A: Prevents phosphorylation and activation by STK11/LKB1 complex. Reduced inhibition of CRTC3-mediated transcriptional activity."" /evidence=""ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:29211348""	SIK1	SIK1_P57059	SIK1_P57059_182	SIK1_P57059	6908	182	T	T182A	P57059_T182A	D
P57059	T	473	E	/note=""T->E: Reduced but still present interaction with 14- 3-3 proteins in response to cAMP signaling and, thus, still able to inhibit TORC activity."" /evidence=""ECO:0000269|PubMed:29211348""	SIK1	SIK1_P57059	SIK1_P57059_473	SIK1_P57059	7319	473	T	T473E	P57059_T473E	D
P57059	S	575	E	/note=""S->E: Strongly reduced but still present interaction with 14-3-3 proteins in response to cAMP signaling and, thus, still able to inhibit TORC activity."" /evidence=""ECO:0000269|PubMed:29211348""	SIK1	SIK1_P57059	SIK1_P57059_575	SIK1_P57059	7421	575	S	S575E	P57059_S575E	D
Q9H3Y6	K	258	M	/note=""K->M: Loss of kinase activity. Exhibits a diffused cytoplasmic localization. No effect on interaction with KHDRBS1 or VIM but abolishes tyrosine phosphorylation of both substrates."" /evidence=""ECO:0000269|PubMed:23822091, ECO:0000269|PubMed:29496907""	SRMS	SRMS_Q9H3Y6	SRMS_Q9H3Y6_258	SRMS_Q9H3Y6	6551	258	K	K258M	Q9H3Y6_K258M	D
Q9Y2H1	T	75	A	/note=""T->A: Decreased kinase activity. Reduced binding of S100B."" /evidence=""ECO:0000269|PubMed:15037617""	ST38L	ST38L_Q9Y2H1	ST38L_Q9Y2H1_75	ST38L_Q9Y2H1	6453	75	T	T75A	Q9Y2H1_T75A	D
Q15831	L	67	P	/note=""L -> P (in PJS; abolishes kinase activity, leading to loss of autophosphorylation; dbSNP:rs137853077)"" /evidence=""ECO:0000269|PubMed:9428765, ECO:0000269|PubMed:9837816"" /id=""VAR_006202""	STK11	STK11_Q15831	STK11_Q15831_67	STK11_Q15831	6507	67	L	L67P	Q15831_L67P	D
Q15831	D	176	N	/note=""D -> N (in PJS; loss of kinase activity, leading to greatly reduced autophosphorylation; fails to phosphorylate PTEN in vitro; no significant effect on nucleocytoplasmic localization; dbSNP:rs730881979)"" /evidence=""ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:9837816"" /id=""VAR_071058""	STK11	STK11_Q15831	STK11_Q15831_176	STK11_Q15831	6815	176	D	D176N	Q15831_D176N	D
Q15831	W	239	C	/note=""W -> C (in PJS; late onset suggests reduced penetrance; dbSNP:rs137853082)"" /evidence=""ECO:0000269|PubMed:12372054"" /id=""VAR_033142""	STK11	STK11_Q15831	STK11_Q15831_239	STK11_Q15831	6965	239	W	W239C	Q15831_W239C	D
Q15831	W	308	C	/note=""W -> C (in PJS; abolishes kinase activity, leading to loss of autophosphorylation; dbSNP:rs1057520042)"" /evidence=""ECO:0000269|PubMed:9837816"" /id=""VAR_071059""	STK11	STK11_Q15831	STK11_Q15831_308	STK11_Q15831	7123	308	W	W308C	Q15831_W308C	D
Q15831	K	78	I	/note=""K->I: Loss of kinase activity, leading to greatly reduced autophosphorylation."" /evidence=""ECO:0000269|PubMed:11430832, ECO:0000269|PubMed:9837816""	STK11	STK11_Q15831	STK11_Q15831_78	STK11_Q15831	6551	78	K	K78I	Q15831_K78I	D
Q15831	K	78	M	/note=""K->M: Loss of kinase activity, leading to reduced autophosphorylation and acting as a dominant-negative mutant."" /evidence=""ECO:0000269|PubMed:11430832, ECO:0000269|PubMed:9837816""	STK11	STK11_Q15831	STK11_Q15831_78	STK11_Q15831	6551	78	K	K78M	Q15831_K78M	D
Q15831	T	189	A	/note=""T->A: Reduced phosphorylation."" /evidence=""ECO:0000269|PubMed:11430832""	STK11	STK11_Q15831	STK11_Q15831_189	STK11_Q15831	6838	189	T	T189A	Q15831_T189A	D
Q15208	T	74	A	/note=""T->A: Decreases autophosphorylation and kinase activity. Reduced binding of S100B."" /evidence=""ECO:0000269|PubMed:12493777""	STK38	STK38_Q15208	STK38_Q15208_74	STK38_Q15208	6453	74	T	T74A	Q15208_T74A	D
Q9UHD2	R	308	Q	/note=""R -> Q (in DALS4; reduced kinase activity)"" /evidence=""ECO:0000269|PubMed:25803835"" /id=""VAR_073941""	TBK1	TBK1_Q9UHD2	TBK1_Q9UHD2_308	TBK1_Q9UHD2	7203	308	R	R308Q	Q9UHD2_R308Q	D
Q9UHD2	R	357	Q	/note=""R -> Q (in DALS4; reduced kinase activity; dbSNP:rs758357594)"" /evidence=""ECO:0000269|PubMed:25803835"" /id=""VAR_073942""	TBK1	TBK1_Q9UHD2	TBK1_Q9UHD2_357	TBK1_Q9UHD2	7252	357	R	R357Q	Q9UHD2_R357Q	D
Q9UHD2	Y	577	A	/note=""Y->A: Decreases kinase activity. Reduced phosphorylation of STING1."" /evidence=""ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:30842653""	TBK1	TBK1_Q9UHD2	TBK1_Q9UHD2_577	TBK1_Q9UHD2	7472	577	Y	Y577A	Q9UHD2_Y577A	D
Q9UHD2	N	578	A	/note=""N->A: Reduced phosphorylation of STING1."" /evidence=""ECO:0000269|PubMed:30842653""	TBK1	TBK1_Q9UHD2	TBK1_Q9UHD2_578	TBK1_Q9UHD2	7473	578	N	N578A	Q9UHD2_N578A	D
Q9UHD2	Q	581	A	/note=""Q->A: Reduced phosphorylation of STING1."" /evidence=""ECO:0000269|PubMed:30842653""	TBK1	TBK1_Q9UHD2	TBK1_Q9UHD2_581	TBK1_Q9UHD2	7476	581	Q	Q581A	Q9UHD2_Q581A	D
P36897	T	204	V	/note=""T->V: Reduced phosphorylation. Reduced response to TGF-beta."" /evidence=""ECO:0000269|PubMed:7774578""	TGFR1	TGFR1_P36897	TGFR1_P36897_204	TGFR1_P36897	6464	204	T	T204V	P36897_T204V	D
Q02763	Y	611	C	/note=""Y -> C (in GLC3E; reduced response to ligand; loss of ligand-induced phosphorylation; no effect on basal membrane location; dbSNP:rs1306527531)"" /evidence=""ECO:0000269|PubMed:27270174"" /id=""VAR_078048""	TIE2	TIE2_Q02763	TIE2_Q02763_611	TIE2_Q02763	6252	611	Y	Y611C	Q02763_Y611C	D
Q02763	C	224	S	/note=""C->S: Reduces protein abundance."" /evidence=""ECO:0000269|PubMed:27270174""	TIE2	TIE2_Q02763	TIE2_Q02763_224	TIE2_Q02763	5865	224	C	C224S	Q02763_C224S	D
P17948	Y	914	F	/note=""Y->F: Reduces phosphorylation at other tyrosine residues."" /evidence=""ECO:0000269|PubMed:9722576""	VGFR1	VGFR1_P17948	VGFR1_P17948_914	VGFR1_P17948	6644	914	Y	Y914F	P17948_Y914F	D
P35968	V	848	E	/note=""V -> E (strongly reduced autophosphorylation and kinase activity; dbSNP:rs1139776)"" /evidence=""ECO:0000269|PubMed:10037737, ECO:0000269|PubMed:1656371"" /id=""VAR_046679""	VGFR2	VGFR2_P35968	VGFR2_P35968_848	NA	NA	NA	NA	V848E	P35968_V848E	D
P35968	R	726	A	/note=""R->A: Strongly reduced autophosphorylation and activation of MAP kinases."" /evidence=""ECO:0000269|PubMed:20080685""	VGFR2	VGFR2_P35968	VGFR2_P35968_726	NA	NA	NA	NA	R726A	P35968_R726A	D
P35968	D	731	A	/note=""D->A: Strongly reduced autophosphorylation and activation of MAP kinases."" /evidence=""ECO:0000269|PubMed:20080685""	VGFR2	VGFR2_P35968	VGFR2_P35968_731	NA	NA	NA	NA	D731A	P35968_D731A	D
P35968	Y	996	F	/note=""Y->F: Strongly reduced autophosphorylation. Reduces phosphorylation of PLCG1."" /evidence=""ECO:0000269|PubMed:10102632""	VGFR2	VGFR2_P35968	VGFR2_P35968_996	NA	NA	NA	NA	Y996F	P35968_Y996F	D
P35916	A	855	T	/note=""A -> T (in LMPHM1; recessive form; results in reduced autophosphorylation; results in impaired ligand- induced receptor internalization and downstream signaling; dbSNP:rs121909657)"" /evidence=""ECO:0000269|PubMed:19289394"" /id=""VAR_074044""	VGFR3	VGFR3_P35916	VGFR3_P35916_855	VGFR3_P35916	6478	855	A	A855T	P35916_A855T	D
P35916	Y	1230	F	/note=""Y->F: Loss of phosphorylation site. Strongly reduces stimulation of cell proliferation and cell migration."" /evidence=""ECO:0000269|PubMed:12881528, ECO:0000269|PubMed:16076871""	VGFR3	VGFR3_P35916	VGFR3_P35916_1230	VGFR3_P35916	7187	1230	Y	Y1230F	P35916_Y1230F	D
P35916	Y	1231	F	/note=""Y->F: Loss of phosphorylation site. Strongly reduces stimulation of cell proliferation and cell migration."" /evidence=""ECO:0000269|PubMed:12881528, ECO:0000269|PubMed:16076871""	VGFR3	VGFR3_P35916	VGFR3_P35916_1231	VGFR3_P35916	7188	1231	Y	Y1231F	P35916_Y1231F	D
P35916	Y	1333	F	/note=""Y->F: Loss of phosphorylation site. Reduced autophosphorylation."" /evidence=""ECO:0000269|PubMed:12881528, ECO:0000269|PubMed:7675451""	VGFR3	VGFR3_P35916	VGFR3_P35916_1333	VGFR3_P35916	7290	1333	Y	Y1333F	P35916_Y1333F	D
P35916	Y	1337	F	/note=""Y->F: Reduced autophosphorylation. Strongly reduces stimulation of cell proliferation and cell migration."" /evidence=""ECO:0000269|PubMed:12881528, ECO:0000269|PubMed:20431062, ECO:0000269|PubMed:7675451""	VGFR3	VGFR3_P35916	VGFR3_P35916_1337	VGFR3_P35916	7294	1337	Y	Y1337F	P35916_Y1337F	D
P35916	Y	1363	F	/note=""Y->F: Loss of phosphorylation site. Slightly reduced autophosphorylation."" /evidence=""ECO:0000269|PubMed:12881528, ECO:0000269|PubMed:7675451""	VGFR3	VGFR3_P35916	VGFR3_P35916_1363	VGFR3_P35916	7320	1363	Y	Y1363F	P35916_Y1363F	D
Q99986	S	342	A	/note=""S->A: Abolishes phosphorylation by PLK3 and induction of Golgi fragmentation during mitosis. Strongly reduced autophosphorylation."" /evidence=""ECO:0000269|PubMed:19103756, ECO:0000269|PubMed:21543316""	VRK1	VRK1_Q99986	VRK1_Q99986_342	VRK1_Q99986	7179	342	S	S342A	Q99986_S342A	D
Q99986	T	353	A	/note=""T->A: Strongly reduced autophosphorylation."" /evidence=""ECO:0000269|PubMed:21543316""	VRK1	VRK1_Q99986	VRK1_Q99986_353	VRK1_Q99986	7190	353	T	T353A	Q99986_T353A	D
